journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thrombosis and Haemostasis: JTH

journal
https://www.readbyqxmd.com/read/28333412/boycott
#1
EDITORIAL
F R Rosendaal, P H Reitsma
No abstract text is available yet for this article.
March 23, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28322016/haemostatic-effects-of-the-ticagrelor-antidote-medi2452-in-pigs-treated-with-ticagrelor-on-a-background-of-aspirin
#2
Susanne Pehrsson, Karin J Johansson, Annika Janefeldt, Ann-Sofie Sandinge, Sufyan Maqbool, Joanne Goodman, José Sanchez, Joachim Almquist, Peter Gennemark, Sven Nylander
BACKGROUND: Ticagrelor, a P2Y12 antagonist, is approved for the prevention of thromboembolic events. However, antiplatelet therapies carry a risk of bleeding. OBJECTIVE: To explore the haemostatic effects of MEDI2452, an antidote for ticagrelor. METHODS: Pigs, pre-treated with aspirin, were given an intravenous infusion of ticagrelor or vehicle. After stop of infusion, a piece of a liver lobe was cut off, and a bolus of MEDI2452 or vehicle was administered intravenously...
March 21, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28317330/long-term-risk-of-venous-thromboembolism-recurrence-after-isolated-superficial-vein-thrombosis
#3
Jean-Philippe Galanaud, Marie-Antoinette Sevestre, Gilles Pernod, Susan R Kahn, Céline Genty, Hugo Terrisse, Dominique Brisot, Jean-Luc Gillet, Isabelle Quéré, Jean-Luc Bosson
BACKGROUND: Isolated superficial vein thrombosis (iSVT) (without concomitant deep vein thrombosis (DVT) or pulmonary embolism (PE)) is a frequent event but available data on long-term outcomes are scarce and retrospective. Therefore, we aimed to determine prospectively the risk and type of venous thromboembolic (VTE) recurrence after iSVT and compare it with that of proximal DVT. METHODS: Using data from the prospective, multicentre, observational, OPTIMEV study, we assessed at three years and after anticoagulants were stopped, the incidence and the type of VTE recurrence (iSVT/DVT/PE) of patients with a first objectively confirmed iSVT without cancer (n=285) and compared this to patients with a first proximal DVT without cancer (n=262)...
March 20, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28316135/variability-of-cut-off-values-for-the-detection-of-lupus-anticoagulants-results-of-an-international-multicenter-multiplatform-study
#4
Armando Tripodi, Veena Chantarangkul, Michela Cini, Katrien Devreese, Jeffrey S Dlott, Roberta Giacomello, Elaine Gray, Cristina Legnani, Marta E Martinuzzo, Paola Pradella, Annelie Siegemund, Sitalakshmi Subramanian, Pierre Suchon, Sophie Testa
BACKGROUND: Cut-off values for results interpretation of lupus anticoagulant (LA) detection are poorly investigated. AIMS: (i) To assess whether results from healthy donors were normally distributed and (ii) the between-laboratories differences of cut-off values for screening, mixing and LA confirmation when calculated as 99(th) or 95(th) centiles, and (iii) to assess their impact on LA detection-rate. METHODS: Each of 11 labs using one of the 3 widely-used commercial platforms for LA detection was asked to collect plasmas from 120 healthy donors and to perform screening, mixing and LA confirmation with two methods (activated partial thromboplastin time [APTT]- and dilute Russell viper venom [dRVV]-derived)...
March 17, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28316124/anticoagulation-in-patients-with-isolated-distal-deep-vein-thrombosis-a-meta-analysis
#5
Laura Franco, Michela Giustozzi, Giancarlo Agnelli, Cecilia Becattini
BACKGROUND: The optimal management of patients with isolated distal deep vein thrombosis (IDDVT) concerning both the need for anticoagulation and its duration is undefined. OBJECTIVES: We performed a meta-analysis of randomized and cohort studies in patients with IDDVT to assess the clinical benefit of i) anticoagulation versus no anticoagulation and ii) anticoagulant treatment for 6 weeks vs. more than 6 weeks. METHODS: The primary outcome of this analysis was recurrent venous thromboembolism (proximal propagation, recurrence of deep vein thrombosis and pulmonary embolism)...
March 17, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28301715/athletes-and-blood-clots-individualized-intermittent-anticoagulation-management
#6
LETTER
Joshua N Berkowitz, Stephan Moll
Athletes with venous thromboembolism (VTE) are typically prohibited from participating in contact sports during anticoagulation therapy, but such mandatory removal from competition can cause psychological and financial detriments for athletes and overlooks patient autonomy. The precedent of compulsory removal developed when options for anticoagulation therapy were more limited, but medical advances now allow for rethinking of the management of athletes with VTE. We propose a novel therapeutic approach to the treatment of athletes who participate in contact sports and require anticoagulation...
March 16, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28296243/measurement-of-platelet-aggregation-independent-of-patient-platelet-count-a-flow-cytometric-approach
#7
Pernille Just Vinholt, Henrik Frederiksen, Anne-Mette Hvas, Ulrik Sprogøe, Christian Nielsen
BACKGROUND: Methods for testing platelet aggregation in thrombocytopenia are missing. OBJECTIVE: To establish a flow cytometric test of in vitro platelet aggregation independent of the patient platelet count and examined the association of aggregation with bleeding history in thrombocytopenic patients. PATIENTS/METHODS: We established a flow cytometric assay of platelet aggregation and measured samples from healthy individuals pre-incubated with antiplatelet drugs and samples from two patients with inherited platelet disorders...
March 15, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28296129/comparing-thrombin-generation-in-patients-with-hemophilia-a-and-patients-on-vitamin-k-antagonists
#8
M L Y de Koning, K Fischer, B de Laat, A Huisman, M Ninivaggi, R E G Schutgens
BACKGROUND: It is unknown whether patients with hemophilia A with atrial fibrillation require treatment with vitamin K antagonists (VKA) to the same extent as the normal population. OBJECTIVE: To compare hemostatic potential in hemophilia patients and patients on VKA using thrombin generation (TG). METHODS: In this cross-sectional study, TG, initiated with 1pM tissue factor, was measured in 133 patients with severe (FVIII <1%, n=15) and non-severe (FVIII 1-50%, n=118) hemophilia A, 97 patients on VKA with an international normalized ratio (INR) ≥1...
March 15, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28294526/phase-1-dose-escalating-study-of-the-safety-pharmacokinetics-and-pharmacodynamics-of-activated-factor-x-i-16l
#9
Dana Parsons-Rich, Fei Hua, Gang Li, Constantino Kantaridis, Debra D Pittman, Steven Arkin
BACKGROUND: FXa(I16L) (PF-05230907) is a zymogen-like variant of activated coagulation factor X (FXa). It exhibits enhanced resistance to inactivation by endogenous inhibitors compared with wild-type FXa and restores hemostatic activity in nonclinical models of various bleeding conditions. OBJECTIVES: To evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FXa(I16L) , a phase 1, first-in-human, dose escalation clinical trial in healthy adult volunteers was conducted METHODS: Participants were assigned to 1 of 6 ascending single-dose cohorts (0...
March 14, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28296069/thrombotic-and-bleeding-outcomes-following-perioperative-interruption-of-direct-oral-anticoagulants-in-patients-with-venous-thromboembolic-disease
#10
J Shaw, C de Wit, G Le Gal, M Carrier
BACKGROUND: Direct Oral Anticoagulants (DOACs) are increasingly being used in the setting of venous thromboembolic disease (VTE). There is little evidence to guide the peri-procedural interruption of DOACs in this patient population. A number of studies have evaluated the perioperative interruption of DOACs based on half-life of the anticoagulant and the underlying procedural bleeding risk in patient with atrial fibrillation, but it remains unclear whether these findings can be extended to patients with VTE...
March 12, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28294559/the-platelet-activating-receptor-c-type-lectin-receptor-2-plays-an-essential-role-in-liver-regeneration-after-partial-hepatectomy-in-mice
#11
Hiroshi Kono, Hideki Fujii, Katsue Suzuki-Inoue, Osamu Inoue, Shinji Furuya, Kazuyoshi Hirayama, Yasuhiro Akazawa, Yuuki Nakata, Chao Sun, Nagaharu Tsukiji, Toshiaki Shirai, Yukio Ozaki
BACKGROUND AND AIM: The aim of the present study was to investigate the role of CLEC-2 in liver regeneration following partial liver resection in mice. MATERIALS AND METHODS: Irradiated chimeric mice transplanted with fetal liver cells from wild-type (WT), CLEC-2 deleted (KO), or CLEC-2 deleted specifically from platelets (flKO) mice were generated. Mice underwent 70% partial hepatectomy (PH). Immunohistochemical staining was performed to investigate the expression of the endogenous ligand for CLEC-2, podoplanin...
March 12, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28294518/disruption-of-protein-complexes-containing-protein-phosphatase-2b-and-munc18c-dampens-the-secretion-of-von-willebrand-factor-from-endothelial-cells
#12
Qi Da, Tanner Shaw, Subhashree Pradhan, Paul A Roche, Miguel A Cruz, K Vinod Vijayan
BACKGROUND: Aberrant secretion of von Willebrand factor (VWF) from endothelial cells contributes to inflammation and vascular thrombosis. Agonist-induced VWF secretion is facilitated by protein kinase and phosphatase-mediated signaling. Although the catalytic subunit of protein phosphatase 2B (PP2B-Aα) is targeted to the secretory machinery via an interaction with the vesicle trafficking protein, Munc18c in endothelial cells, the functional relevance of this phosphatase complex is unclear...
March 12, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28296036/targeting-of-c-type-lectin-like-receptor-2-or-p2y12-for-the-prevention-of-platelet-activation-by-immunotherapeutic-cpg-oligodeoxynucleotides
#13
C Delierneux, N Donis, L Servais, O Wéra, C Lecut, M Vandereyken, L Musumeci, S Rahmouni, J Schneider, J A Eble, P Lancellotti, C Oury
BACKGROUND: Synthetic phosphorothioate-modified CpG oligodeoxynucleotides (CpG ODNs) display potent immunostimulatory properties that are widely exploited in clinical trials of anticancer treatment. Unexpectedly, a recent study indicates that CpG ODNs activate human platelets via the immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptor glycoprotein VI. OBJECTIVE: To further analyze the mechanisms of CpG ODN-induced platelet activation and identify potential inhibitory strategies...
March 11, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28267256/shear-sensitive-nanocapsule-drug-release-for-site-specific-inhibition-of-occlusive-thrombus-formation
#14
Christopher P Molloy, Yu Yao, Helene Kammoun, Thomas Bonnard, Thomas Hoefer, Karen Alt, Francisco Tovar-Lopez, Gary Rosengarten, Paul A Ramsland, Andries D van der Meer, Albert van den Berg, Andrew J Murphy, Christoph E Hagemeyer, Karlheinz Peter, Erik Westein
BACKGROUND: Myocardial infarction and stroke remain the leading causes of mortality and morbidity. The major limitation of current antiplatelet therapy is that their effective concentrations are limited due to bleeding complications. Targeted delivery of antiplatelet drug to sites of thrombosis would overcome these limitations. OBJECTIVES: Here, we have exploited a key biomechanical feature specific to thrombosis; significantly increased blood shear stress due to a reduction in the lumen of the vessel, to achieve site directed delivery of the clinically used antiplatelet agent eptifibatide using shear-sensitive phosphatidylcholine based nanocapsules...
March 7, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28267249/once-versus-twice-daily-aspirin-after-coronary-bypass-surgery-a-randomized-trial
#15
J S Paikin, J Hirsh, J S Ginsberg, J I Weitz, N C Chan, R P Whitlock, G Pare, J W Eikelboom
BACKGROUND: Acetyl-salicylic acid (ASA) hyporesponsiveness occurs transiently after coronary artery bypass graft surgery (CABG) surgery and may compromise the effectiveness of ASA to reduce thrombotic graft failure. Reduced response to ASA 81mg once-daily after CABG surgery is overcome by four times-daily ASA dosing. OBJECTIVES: To determine whether ASA 325mg once-daily or 162mg twice-daily overcomes reduced response to ASA 81mg once-daily after CABG surgery. METHODS: Adults undergoing CABG surgery were randomized to ASA 81mg once-daily, 325mg once-daily or 162mg twice-daily...
March 7, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28266773/long-term-outcomes-of-cancer-related-isolated-distal-deep-vein-thrombosis-the-optimev-study
#16
Jean-Philippe Galanaud, Marie-Antoinette Sevestre, Gilles Pernod, Céline Genty, Sébastien Richelet, Susan R Kahn, Carine Boulon, Hugo Terrisse, Isabelle Quéré, Jean-Luc Bosson
BACKGROUND: Isolated distal deep vein thrombosis (iDDVT) (infra-popliteal DVT without pulmonary embolism [PE]) is a frequent event and, in the absence of cancer, is usually considered to be a minor form of venous thromboembolism (VTE). However, the clinical significance of cancer-related iDDVT is unknown. METHODS: Using data from the observational, prospective multicentre OPTIMEV cohort, we compared, at 3 years, the incidences of death, VTE recurrence and major bleeding in patients with cancer-related iDDVT with cancer patients with isolated proximal DVT (matched 1:1 on age and sex) and with patients with iDDVT without cancer (matched 1:2 on age and sex)...
March 7, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28244200/population-pharmacokinetics-of-recombinant-coagulation-factor-viii-singlechain-in-patients-with-severe-hemophilia-a
#17
Y Zhang, J Roberts, M Tortorici, A Veldman, K St Ledger, A Feussner, J Sidhu
BACKGROUND: rVIII-SingleChain is a unique recombinant factor VIII (FVIII) molecule. OBJECTIVES: To (i) characterize the population pharmacokinetics (PK) of rVIII-SingleChain in severe hemophilia A patients, (ii) identify correlates of variability in rVIII-SingleChain PK, and (iii) simulate various dosing scenarios of rVIII-SingleChain. PATIENTS/METHODS: A population PK model was developed based on FVIII activity levels of 130 severe hemophilia A patients (n = 91 for ≥ 12 to 65 years; n = 39 for 1 to < 12 years) who had participated in a single-dose PK investigation with rVIII-SingleChain 50 IU kg(-1) ...
February 28, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28239987/effects-of-alloantibodies-to-human-leukocyte-antigen-on-endothelial-expression-and-serum-levels-of-thrombomodulin
#18
S Béland, P Vallin, O Désy, E Lévesque, S A De Serres
Essentials The effect of alloantibodies on the endothelial expression of thrombomodulin is unknown. Thrombomodulin was quantified in stimulated endothelial cells and measured in serum samples. Anti-human leukocyte antigen (HLA) I vs. II antibodies have different effects on thrombomodulin. Anti-HLA II antibodies may promote a prothrombotic state and contribute to microangiopathy. SUMMARY: Rationale Thrombomodulin (TBM) is an anticoagulant and anti-inflammatory transmembrane protein expressed on endothelial cells...
February 26, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28231636/personalized-thromboprophylaxis-using-a-risk-score-for-the-management-of-pregnancies-with-high-risk-of-thrombosis-a-prospective-clinical-study
#19
Y Dargaud, L Rugeri, C Fleury, C Battie, P Gaucherand, C Huissoud, R C Rudigoz, H Desmurs-Clavel, J Ninet, M C Trzeciak
BACKGROUND: Patients with thrombophilia and/or a history of venous thromboembolism (VTE) are at risk of thrombosis during pregnancy. A risk score for pregnancies with increased risk of VTE was previously described by our group (Lyon-VTE-score). OBJECTIVES: The aim of this prospective study was to assess the efficacy and safety of our score-based prophylaxis strategy in 542 pregnancies managed between 2005 and 2015 in Lyon University Hospitals. PATIENTS/METHODS: Of 445 patients included in the study, 36 had several pregnancies during the study period...
February 23, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28222250/long-term-treatment-of-cancer-associated-thrombosis-the-choice-of-the-optimal-anticoagulant
#20
REVIEW
I Elalamy, I Mahé, W Ageno, G Meyer
Patients with cancer associated thrombosis (CAT) carry a higher risk of recurrence, bleeding and mortality as compared to non-cancer patients. The specific profile of cancer patients combining frequent co-morbidities, the use of anti-tumoral therapies and the cancer progression itself represent a major therapeutic challenge for choosing a long-term anticoagulant treatment. This review discusses the practical basis of that choice among available drugs for the long-term antithrombotic strategy linked to their pharmacology, mechanism of action, evidence of clinical benefits, advantages and limitations in such a complex clinical context...
February 21, 2017: Journal of Thrombosis and Haemostasis: JTH
journal
journal
20181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"